ArticleSleep2025
Narcolepsy and risk of cardiovascular outcomes beyond stimulant use.
Article in Sleep, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Assessing mortality risk in narcolepsy: Evidence from population studies.PCN reports : psychiatry and clinical neurosciences · 2026Review
- Cardiovascular risk in narcolepsy: Comparison of type 1 and type 2 in a real-world cohort.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026Article
- Social determinants of health, clinical outcomes, and healthcare resource utilization in participants with and without narcolepsy in theSleep advances : a journal of the Sleep Research Society · 2026Article
- Article
- Sleep and Stroke-An Overlooked Bidirectional Influence: Why Should Sleep and Vascular Neurologists Work Closer?Journal of clinical medicine · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
STUDY
objectivesWe aimed to assess associations between narcolepsy and cardiovascular disease risk while accounting for stimulant use in clinical practice.
methodsUsing 2005-2021 MarketScan Commercial and Medicare Supplemental databases, we identified patients with newly diagnosed narcolepsy using International Classification of Diseases, Ninth or Tenth, Clinical Modification diagnosis codes, were matched at a ratio of 1:3 patients without narcolepsy or hypersomnia using propensity score matching based on baseline demographics, comorbidities, and medication use. Primary outcomes included time to first (1) composite cardiovascular disease event and (2) major adverse cardiac event. Multivariable Cox proportional hazards regression models were used to compare outcome risks between groups, following PS matching, adjusting for time-fixed and time-varying variables, including stimulant use. Individual outcomes were examined separately and analyses were stratified by age, sex, and selected comorbidities.
resultsAfter PS matching, data from 134967 patients (mean [SD] age, 39.9 [16.8] years; 61.5% female) were included in final analyses. Following adjustment of baseline and time-varying covariates, patients with narcolepsy had increased risks of cardiovascular disease (adjusted hazard ratio, 1.89 [95% CI = 1.71 to 2.09]) and major adverse cardiac event (adjusted hazard ratio,1.95 [95% CI = 1.70 to 2.23]) compared with patients without narcolepsy. Results remained consistent across individual cardiovascular diseases and major adverse cardiac events. Subgroup analyses yielded similar findings.
conclusionsAfter adjusting for stimulant use, this cohort study found that patients with narcolepsy experienced increased risk of developing cardiovascular disease compared with patients without narcolepsy. This finding suggests that patients with narcolepsy may benefit from routine screening and monitoring for cardiovascular events. Statement of Significance This study enhances our understanding of the association between narcolepsy and cardiovascular events by employing a robust causal inference framework and adjusting for medications used to manage narcolepsy symptoms, which are known to be associated with cardiovascular risk. The large population-based cohort study included 34 562 patients with narcolepsy and 100 405 propensity score-matched patients without narcolepsy. Patients with narcolepsy had an increased risk of developing cardiovascular events compared to without narcolepsy controls, even after adjusting for medication use, including stimulants. These findings highlight the importance of routine cardiovascular screening and monitoring for patients with narcolepsy to mitigate potential risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.